Detailed performance report for SO YOUNG covering Q2 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: In Q2 2026, aesthetic treatment services revenue reached RMB 331.4 million, up about 130% YoY and the 10th straight quarter of triple-digit growth. Total revenue hit an all-time high, up 33% YoY. Gross margin improved by 3.8 percentage points YoY and 1 point QoQ. Net loss attributable to So-Young narrowed to RMB 22.7 million from RMB 36.0 million, while non-GAAP net loss narrowed to RMB 21.0 million. Basic and diluted loss per ADS were RMB 0.22 versus RMB 0.35 last year. Cash and investments totaled RMB 848.2 million.
Company Outlook & Strategy: Management emphasized disciplined growth over pure expansion, focusing on improving unit economics, profitability, and sustainable scale. Q3 guidance for aesthetic treatment services revenue is RMB 352 million to RMB 362 million, implying 91.7% to 97.2% YoY growth. The company expects continued gross margin improvement in Q3 and Q4, supported by scale, better center utilization, and stronger operating leverage. AI integration and a “fully intelligent center” rollout in Q4 are key strategic priorities.
Key Industry Trends: Demand is shifting toward natural restoration, tissue regeneration, and longer-lasting outcomes, supporting collaboration with upstream partners like Jinbo. The company is using real-world data and clinic network insights to influence product development, supply chain decisions, and innovation. Management also highlighted growing importance of digital infrastructure and AI in standardizing medical aesthetic delivery and expanding premium care access into lower-tier cities.
Operational Highlights: The company operated 65 So-Young clinics across 18 major cities as of June 30, adding 11 centers in the quarter. Of these, 47 were profitable and 51 generated positive operating cash flow. Same-store sales growth reached 52%, up from 14% last year. Management raised the capacity utilization benchmark by 50%, improved staffing and workflow efficiency, and expanded AI use in product authentication, quality control, SOPs, and physician training. R&D expense fell 21.7% YoY due to improved staff efficiency.
Challenges & Risks: Non-core segments weakened, with information and reservation service revenue down 35% YoY, medical products and maintenance down 2.8%, and other services down 48.2%. Management noted that rapid expansion creates pressure on organizational capabilities, compliance, and user experience. The business also faces revenue deferral from loyalty programs and treatment protocols, which tempers near-term recognized revenue. Continued margin improvement depends on execution, procurement leverage, and sustained customer acquisition efficiency.
Key Analyst Questions & Responses: Analysts asked about the Jinbo partnership, AI applications, gross margin expansion, and the path to profitability. Management said the Jinbo collaboration supports long-term growth through upstream integration, data-driven product and supply chain decisions, and co-creation based on real-world clinical feedback. On AI, the company said its role is to make treatments more standardized, traceable, and scalable, with immediate focus on authentication, back-end quality control, data governance, and physician training. On margins and profitability, management pointed to scale, higher utilization, supply chain leverage, exclusive OEM deals, and AI-enabled efficiency; it expects meaningful clinic gross margin improvement in Q3 and Q4 and said group-level profitability is becoming achievable.
Access the official earnings call transcript for SO-YOUNG 2026 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.